Nedizantrep

GDC-6599 is an orally active TRPA1 inhibitor, with IC50 values of 5.3 nM in humans, 6.6 nM in rats, 9.3 nM in dogs, 7.2 nM in monkeys, and 15 nM in guinea pigs. GDC-6599 can be used in the research of neuropathic pain and respiratory diseases such as asthma and chronic cough[1].

Product Specifications

CAS Number

[2376824-99-4]

Product Name Alternative

GDC-6599

UNSPSC

12352005

Target

TRP Channel

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/gdc-6599.html

Concentration

10mM

Purity

99.77

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C1C2=C(N=CN2C)N=C(N1CC3=NC([C@H]4C[C@H](C5=CC=C(C=C5)Cl)OC4)=NO3)C

Molecular Formula

C20H19ClN6O3

Molecular Weight

426.86

References & Citations

[1]Terrett JA, et al. Discovery of TRPA1 Antagonist GDC-6599: Derisking Preclinical Toxicity and Aldehyde Oxidase Metabolism with a Potential First-in-Class Therapy for Respiratory Disease. J Med Chem. 2024 Mar 14;67 (5) :3287-3306. doi: 10.1021/acs.jmedchem.3c02121. Epub 2024 Mar 3. PMID: 38431835.